Market
Will Datroway lead market share for advanced HR-positive, HER2-negative breast cancer in US by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market share data from pharmaceutical market research firms
Story
FDA Approves Datroway for Advanced HR-Positive, HER2-Negative Breast Cancer
Jan 21, 2025, 02:03 AM
AstraZeneca and Daiichi Sankyo's new cancer drug, Datroway (datopotamab deruxtecan), has received FDA approval for treating advanced HR-positive, HER2-negative breast cancer. The drug, an antibody-drug conjugate targeting the TROP2 protein, is designed for patients whose cancer has progressed after endocrine therapy and chemotherapy. Results from the TROPION-Breast01 Phase III trial showed Datroway reduced the risk of disease progression or death by 37% compared to chemotherapy, with a median progression-free survival of 6.9 months versus 4.9 months for chemotherapy. While the drug demonstrated significant efficacy in progression-free survival, it fell short of statistical significance in overall survival improvement. Datroway is part of AstraZeneca's broader oncology strategy, marking its eighth new medicine approved in the U.S. as part of its goal to launch 20 new drugs by 2030. The drug's approval adds to the growing list of targeted therapies for breast cancer, offering a new treatment option for patients with limited alternatives.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 20% • 25%
20-40% • 25%
40-60% • 25%
More than 60% • 25%
Less than 10% • 25%
20% to 30% • 25%
10% to 20% • 25%
More than 30% • 25%
Less than 10% • 25%
More than 30% • 25%
10% to 20% • 25%
20% to 30% • 25%
Yes • 50%
No • 50%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
No • 50%
Yes • 50%
One • 25%
None • 25%
More than two • 25%
Two • 25%
20% to 40% • 25%
More than 60% • 25%
Less than 20% • 25%
40% to 60% • 25%
Verzenio (abemaciclib) • 25%
Kisqali (ribociclib) • 25%
Other • 25%
Enhertu (trastuzumab deruxtecan) • 25%
Pfizer • 25%
Novartis • 25%
Other • 25%
Roche • 25%